Intra-Cellular Therapies (BSP:I2TC34) Additional Paid-In Capital : R$11,117 Mil(As of Mar. 2024)

View and export this data going back to 2023. Start your Free Trial

What is Intra-Cellular Therapies Additional Paid-In Capital?

Intra-Cellular Therapies's quarterly additional paid-in capital increased from Sep. 2023 (R$10,819 Mil) to Dec. 2023 (R$10,821 Mil) and increased from Dec. 2023 (R$10,821 Mil) to Mar. 2024 (R$11,117 Mil).

Intra-Cellular Therapies's annual additional paid-in capital increased from Dec. 2021 (R$9,271 Mil) to Dec. 2022 (R$11,213 Mil) but then declined from Dec. 2022 (R$11,213 Mil) to Dec. 2023 (R$10,821 Mil).

Intra-Cellular Therapies Additional Paid-In Capital Historical Data

The historical data trend for Intra-Cellular Therapies's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Intra-Cellular Therapies Additional Paid-In Capital Chart

Intra-Cellular Therapies Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

3,714.46

8,197.96

9,271.07

11,213.29

10,821.06

Intra-Cellular Therapies Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															11,208.06	10,550.35	10,818.65	10,821.06	11,116.53

Intra-Cellular Therapies Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Intra-Cellular Therapies Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Intra-Cellular Therapies's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Intra-Cellular Therapies (BSP:I2TC34) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Intra-Cellular Therapies Inc (BSP:I2TC34) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

ITCI:USA ITCI:Mexico 23I:Germany

Address

430 East 29th Street, New York, NY, USA, 10016

Website

https://www.intracellulartherapies.com

Intra-Cellular Therapies Inc is a biopharmaceutical company that develops novel drugs for treating diseases of the central nervous system. The company is focused on the delivery and clinical development of small-molecule drugs that address needs in neuropsychiatric and neurological disorders. Intra-Cellular maintains proprietary chemistry platforms to develop drugs for neurodegenerative diseases. The company's business segment is discovering and developing drugs for the treatment of neurological and psychiatric disorders.

Intra-Cellular Therapies (BSP:I2TC34) Headlines

No Headlines